--- title: "Zevra Therapeutics (ZVRA) news: lawsuit and settlement" url: "https://aibio.space/companies/zevra-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ZVRA lawsuit and settlement news: Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million. Zevra Therapeutics, Inc." --- ZVRA Zevra Therapeutics, Inc. NASDAQ · United States # Zevra Therapeutics (ZVRA) news ZVRA lawsuit and settlement news Distress · 2026-03-16 ## [Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million](https://aibio.space/news/zevra-agrees-sell-sdx-portfolio-commave-therapeutics-50-million/) The deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing. ## Latest Zevra Therapeutics news 1. 2025-04-07 Mergers [Zevra Therapeutics closes $150 million sale of rare pediatric disease priority review voucher](https://aibio.space/news/zevra-therapeutics-closes-150-million-sale-rare-pediatric-disease/) Zevra received gross proceeds of $150.0 million at the April 1, 2025 closing. The press release puts net cash proceeds at $148.3 million and cash, cash equivalents and investments at approximately $68.7 million on March 31, 2025. 2. 2025-02-27 Financings [Zevra Therapeutics agrees to sell priority review voucher for $150 million](https://aibio.space/news/zevra-therapeutics-agrees-sell-priority-review-voucher-150-million/) The company expects the sale to close within 30 to 45 days, subject to customary conditions including a Hart-Scott-Rodino waiting period. ## Zevra Therapeutics at a glance - **Ticker**: ZVRA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $221.6 million ### Related companies - [Cellectar Biosciences](https://aibio.space/companies/cellectar-biosciences/) NASDAQ: CLRB - [Nektar Therapeutics](https://aibio.space/companies/nektar-therapeutics/) NASDAQ: NKTR - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX - [Context Therapeutics](https://aibio.space/companies/context-therapeutics/) NASDAQ: CNTX - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) NASDAQ: SKYE - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) NASDAQ: PBLS - [Aytu BioPharma](https://aibio.space/companies/aytu-biopharma/) NASDAQ: AYTU - [Phathom Pharmaceuticals](https://aibio.space/companies/phathom-pharmaceuticals/) NASDAQ: PHAT ### Also on NASDAQ - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) BDTX - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) CBIO - [RenovoRx](https://aibio.space/companies/renovorx/) RNXT - [Champions Oncology](https://aibio.space/companies/champions-oncology/) CSBR - [Mustang Bio](https://aibio.space/companies/mustang-bio/) MBIO - [NEXGEL, INC.](https://aibio.space/companies/nexgel/) NXGL ## What Zevra Therapeutics does Zevra Therapeutics is a commercial-stage company with a late-stage pipeline focused on rare diseases. Its lead product, MIPLYFFA (arimoclomol), is FDA approved for use with miglustat for neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older. It is available through an expanded access program in France, Germany and other EU member states and in select territories outside Europe, and a marketing authorization application for it is under review by the European Medicines Agency. OLPRUVA (sodium phenylbutyrate) for oral suspension is commercially available in the United States for certain urea cycle disorders. Zevra acquired Acer Therapeutics in November 2023, which brought in celiprolol for vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen (COL3A1) mutation. Celiprolol is in a Phase 3 trial called DiSCOVER. The company is also developing KP1077, a serdexmethylphenidate candidate, for idiopathic hypersomnia and narcolepsy. AZSTARYS, developed on Zevra's Ligand Activated Technology platform, is FDA approved and partnered, and Zevra receives royalties and milestones on its net sales. The company plans to expand its pipeline through inorganic growth. | Product or program | What it is | Stage | |---|---|---| | MIPLYFFA (arimoclomol) | Oral treatment used with miglustat for neurological manifestations of Niemann-Pick disease type C | FDA approved | | OLPRUVA (sodium phenylbutyrate) | Oral suspension for certain urea cycle disorders | FDA approved | | Celiprolol | Treatment for vascular Ehlers-Danlos syndrome with a COL3A1 mutation | Phase 3 | | KP1077IH | Serdexmethylphenidate for idiopathic hypersomnia | Phase 3 trial ready | | AZSTARYS | Serdexmethylphenidate and dexmethylphenidate for attention deficit and hyperactivity disorder | FDA approved and partnered | Summarised from the company's [10-K filed Mar 9, 2026](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm). ## Zevra Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [$83.2 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/) | [-$105.5 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/) | | Cash from operations | [-$1.6 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/) | [-$69.7 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/) | | Cash and equivalents | [$62.4 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000068/) | [$33.8 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/) | | Short-term investments | [$128.6 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000068/) | [$35.7 million](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $145.3 million, plus short-term investments of $76.2 million, $221.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Zevra Therapeutics Is Zevra Therapeutics involved in a lawsuit? Our latest story on this, dated Mar 16, 2026: "Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/zevra-agrees-sell-sdx-portfolio-commave-therapeutics-50-million/). Has Zevra Therapeutics settled a lawsuit? Our latest story on this, dated Mar 16, 2026: "Zevra agrees to sell SDX portfolio to Commave Therapeutics for $50 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/zevra-agrees-sell-sdx-portfolio-commave-therapeutics-50-million/). What is the ticker symbol of Zevra Therapeutics? Zevra Therapeutics, Inc. trades under the ticker ZVRA on NASDAQ. Where is Zevra Therapeutics listed? Zevra Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1GDA; LS:A2QLX7; LSX:A2QLX7. What is the SEC CIK of Zevra Therapeutics? The SEC Central Index Key (CIK) for Zevra Therapeutics, Inc. is 1434647. Its filings are on SEC EDGAR. How many shares does Zevra Therapeutics have outstanding? 59,383,781 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Zevra Therapeutics listed under? Our directory records Zevra Therapeutics, Inc. under United States. What does Zevra Therapeutics do? Our directory classifies Zevra Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Zevra Therapeutics? The ISIN recorded for Zevra Therapeutics, Inc. is US4884452065. Does aibio.space cover Zevra Therapeutics? aibio.space lists Zevra Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Zevra Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Zevra Therapeutics develop? Zevra Therapeutics is a commercial-stage company with a late-stage pipeline focused on rare diseases. Its lead product, MIPLYFFA (arimoclomol), is FDA approved for use with miglustat for neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older. What is MIPLYFFA (arimoclomol) from Zevra Therapeutics? MIPLYFFA (arimoclomol): Oral treatment used with miglustat for neurological manifestations of Niemann-Pick disease type C Stage: FDA approved. What is OLPRUVA (sodium phenylbutyrate) from Zevra Therapeutics? OLPRUVA (sodium phenylbutyrate): Oral suspension for certain urea cycle disorders Stage: FDA approved. Is Zevra Therapeutics profitable? Zevra Therapeutics, Inc. reported net income of $83.2 million for the fiscal year ended Dec 31, 2025, and used $1.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Zevra Therapeutics Members talk about Zevra Therapeutics (ZVRA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Zevra Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-16 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/zvra-20260316xex991.htm) 2. 2025-04-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/0001193125-25-073991-index-headers.html) 3. 2025-03-12 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1434647/000143774925007320/zvra20241231_10k.htm) 4. 2025-02-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1434647/000119312525037619/d928575dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ZVRA on TradingView](https://www.tradingview.com/symbols/NASDAQ-ZVRA/). ## SEC filings and registration - **SEC name**: Zevra Therapeutics, Inc. - **CIK**: 1434647 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ZVRA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 101 FEDERAL STREET, BOSTON, MA, 02110 - **Phone**: (888) 958-1253 - **Shares outstanding**: 59,383,781 as of 2026-07-31 (10-Q filed 2026-08-05) - **Former names**: KEMPHARM, INC; KEMPHARM INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000068/zvra-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/zvra-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000041/zvra-20260604.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000031/zvra-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000029/zvra-20260506.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000025/zvra-20260416.htm) filed 2026-04-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000015/zvra-20260312.htm) filed 2026-03-16 - [10-K](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm) filed 2026-03-09 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001434647), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Zevra Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ZVRA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Zevra Therapeutics, Inc. - **Ticker**: ZVRA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US4884452065 - **Other listed symbols**: GETTEX:1GDA; LS:A2QLX7; LSX:A2QLX7 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ZVRA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/zevra-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Zevra Therapeutics (ZVRA) news: lawsuit and settlement", 2026-10-31, https://aibio.space/companies/zevra-therapeutics/